Post by
Mostlyserious on Nov 14, 2022 4:44pm
Q3 out
News release out but full filing not yet available on Sedar. The quarter answers the question of the low share price by those still dubbing this as an opportunity of a lifetime. I suspect if there are those that believe it still, they are going to get a whopper of a discount after these results. Overpromise and underdeliver is no longer a theme for just BioCloud. Obviously they were experiencing challenges that would not see them meet their projections and it looks like they waited to communicate that at the Q filing time because this is where it would become evident. Not good, not good at all. Looking forward to the entertaining spinning by pumpers.
Comment by
Rogg47 on Nov 14, 2022 6:20pm
Geeezzz what can they say?!? AWFULL results, this compagny is getting more and more ridiculous as the months passed by!! After the BC fiasco, now it's the core business fiasco!! Going back under $1 before the end of 2022, "good job" PG...........
Comment by
Mostlyserious on Nov 14, 2022 9:44pm
Well, the thought that he was good at running the core business is now shattered. Not all companies take a bath on higher labour and material costs. Not much of a client base to count on if they make you deliver contracts at a loss. Not very good contracts either if you are taking all the risk.